Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching
暂无分享,去创建一个
[1] R. Zurakowski,et al. A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment , 2008, 2008 American Control Conference.
[2] M. Wainberg,et al. Antiretroviral Therapy , 2008, Drugs.
[3] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] Michael S Saag,et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.
[5] R. Paredes,et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.
[6] S Bonhoeffer,et al. Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Nowak,et al. Pre–existence and emergence of drug resistance in HIV–1 infection , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[8] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[9] Martin S. Hirsch,et al. Treatment for adult HIV infection. , 2004 .
[10] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[11] Haihong Zhu,et al. Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models , 2008, Bulletin of mathematical biology.
[12] X. Xia. ESTIMATION OF HIV/AIDS PARAMETERS , 2002 .
[13] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[14] S. Orsega,et al. Treatment of Adult HIV Infection: Antiretroviral Update and Overview , 2007 .
[15] Michael J. Piovoso,et al. A generalized multi-strain model of HIV evolution with implications for drug-resistance management , 2009, 2009 American Control Conference.
[16] Hulin Wu,et al. Hierarchical Bayesian Methods for Estimation of Parameters in a Longitudinal HIV Dynamic System , 2006, Biometrics.
[17] John Bartlett,et al. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States , 2004 .
[18] Michael S Saag,et al. Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .
[19] Dominik Wodarz,et al. Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment , 2007, 2007 46th IEEE Conference on Decision and Control.
[20] Michael S Saag,et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[21] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] R. Paredes,et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.
[23] A. Telenti,et al. HIV treatment failure: testing for HIV resistance in clinical practice. , 1998, Science.
[24] Somnuek Sungkanuparph,et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[25] Ryan Zurakowski,et al. Resistance Risk Management in HIV Therapy Switching with Explicit Quiescent T-Cell Modeling , 2008 .
[26] D L Barnard,et al. A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it. , 2001, Current medicinal chemistry.